ELIXA trial included patients with recent cardiovascular event (patients with acute coronary syndrome 180 days before randomization), and although there was no benefit in MACE reduction in lixisenatide treated patients compared to placebo, results revealed cardiovascular safety of lixisenatide in this specific high risk population (38, 40)
The two obesity market leaders, with their blockbuster injectables, have left room for an oral, or pill, market to be a new meaningful target for newer players, according to investors
Some studies have shown that between 35 and 50% of patients with FM were not working [7]
The most common side effects are related to the gastrointestinal system
The post-workout shake is produced under the strictest quality standards (IFS Food and GMP)
Spicy foods or herbs do not directly impact BAC levels